2013
DOI: 10.1007/s00044-013-0813-z
|View full text |Cite
|
Sign up to set email alerts
|

Design, synthesis, and evaluation of novel 1-methyl-3-substituted quinazoline-2,4-dione derivatives as antimicrobial agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(5 citation statements)
references
References 17 publications
0
5
0
Order By: Relevance
“…For this reason, the biological screening was expanded to evaluate the antimicrobial activity of alkenes 24a–d and diastereoisomeric mixtures of isoxazolidines ( cis - 20a / trans - 20a (10:90), cis - 20b / trans - 20b (8:92), cis - 20c / trans - 20c (6:94), cis - 20d / trans - 20d (10:90), cis - 21a / trans - 21a (10:90), cis - 21b / trans - 21b (15:85), cis - 21c / trans - 21c (10:90), and cis - 21d / trans - 21d (15:85)) towards selected bacterial strains ( E. faecalis ATCC 29212, S. aureus ATCC 2593, B. cereus PCM 1948, E. coli ATCC 25922, and P. aeruginosa ATCC 27853) and two fungal strains (C. albicans ATCC 10241 and A. brasiliensis ATCC 16404). Previous studies have shown that compounds containing a substituted quinazoline-2,4-dione moiety exhibit promising activity against Gram-negative and Gram-positive bacteria and fungi [ 9 , 23 , 24 , 25 ]. The antimicrobial activity was expressed as the MIC, minimal inhibitory concentrations, and the MBC, minimal bactericidal concentrations.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…For this reason, the biological screening was expanded to evaluate the antimicrobial activity of alkenes 24a–d and diastereoisomeric mixtures of isoxazolidines ( cis - 20a / trans - 20a (10:90), cis - 20b / trans - 20b (8:92), cis - 20c / trans - 20c (6:94), cis - 20d / trans - 20d (10:90), cis - 21a / trans - 21a (10:90), cis - 21b / trans - 21b (15:85), cis - 21c / trans - 21c (10:90), and cis - 21d / trans - 21d (15:85)) towards selected bacterial strains ( E. faecalis ATCC 29212, S. aureus ATCC 2593, B. cereus PCM 1948, E. coli ATCC 25922, and P. aeruginosa ATCC 27853) and two fungal strains (C. albicans ATCC 10241 and A. brasiliensis ATCC 16404). Previous studies have shown that compounds containing a substituted quinazoline-2,4-dione moiety exhibit promising activity against Gram-negative and Gram-positive bacteria and fungi [ 9 , 23 , 24 , 25 ]. The antimicrobial activity was expressed as the MIC, minimal inhibitory concentrations, and the MBC, minimal bactericidal concentrations.…”
Section: Resultsmentioning
confidence: 99%
“…Considerable attention has been focused on studies of antimicrobial and antiviral activities of 1,3-substituted quinazoline-2,4-diones, as some of them have promising biological activity ( Figure 1 ). For example, N 1 -methylquinazoline-2,4-diones 1a–e exhibited high antibacterial properties toward MRSA and B. subtilis and were slightly active against S. aureus [ 9 ], whereas compounds 2a–b appeared to be suitable gyrase inhibitors that are active toward multidrug-resistance Gram-positive bacterial strains [ 10 ]. On the other hand, substituted quinazoline-2,4-dione derivatives 3a–d displayed potent inhibitory activity against respiratory syncytial virus (RSV) (EC 50 = 0.7–2.2 µM) [ 11 ], while compound 4 showed antiviral activity against HIV - 1 and inhibited the recombinant RT in vitro [ 12 ], and N 1 -propargylquinazoline-2,4-dione 5 proved to be active towards adenovirus-2 (EC 50 = 8.3 µM) [ 13 ].…”
Section: Introductionmentioning
confidence: 99%
“…IR (KBr, v max , cm -1 ): 3010, 2958, 1712, 1660, 1623, 1513. 1 Dimethoxy-3-[2-oxo-2-(4-pyridin-4-ylpiperazin-1yl)ethyl]quinazoline-2,4(1H,3H)-dione (34). Compound 6 (0.280 g, 1 mmol) and 1-(4-pyridyl)piperazine (0.163 g, 1 mmol) were reacted according to the general procedure for compounds 7-34 and the crude product was crystallized from methanol-ether mixture to give white powdered crystalline compound; mp: 300 °C (dec), yield: 32 mg (8%).…”
Section: -{4-[(67-dimethoxy-24-dioxo-14-dihydroquinazolin-3(2h)-ymentioning
confidence: 99%
“…Various literatures report numerous 2,4(1H,3H)quinazolinedione analogues showing a wide variety of biological activities such as anticancer [7][8][9][10][11][12][13][14][15][16][17][18][19][20], antimicrobial [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37], antihypertensive [38][39][40], anticonvulsant [41][42][43][44][45][46][47][48][49], anti-inflammatory [50], 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonist [51], phosphodiesterase (PDE) 4 inhibition [52,53], calcium-independent phosphodiesterase enzyme inhibition (CaIPDE) [54], cyclin-dependent kinase 5 (CDK5) inhibition…”
Section: Introductionmentioning
confidence: 99%
“…Several reports have revealed that the unique quinazoline scaffolds possess several and diverse pharmacological activities such as antimicrobial, antimalarial, anticonvulsant, anti-inflammatory, antihypertensive, cholinesterase inhibitory, anti-diabetic, and anticancer activities [1]. Among the most important quinazoline families are quinazoline-2,4(1H,3H)-dione derivatives, and the various studies have reported several analogues representing a wide variety of biological activities, for example, antimicrobial [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18], anticancer [19][20][21][22][23][24][25][26][27][28][29][30][31][32], antiplatelet [33], antihypertensive [34], antioxidant [35], anticonvulsant [36][37][38], anti-inflammatory [39], phosphodiesterase (PDE) 4 inhibition [40], 5-HT3A receptor antagonist [41], and cyclin-dependent kinase 5 (CDK5) inhibition [42].…”
Section: Introductionmentioning
confidence: 99%